Research graph
References from Hypertriglyceridemia: Causes, Consequences, Diagnosis, and Management. Local targets link to admitted publications; unresolved targets remain external evidence.
American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Dyslipidemia‐2025 Update
10.1016/j.eprac.2025.07.014 · 2025 · External reference
Clinical Review on Triglycerides
10.1093/eurheartj/ehz785 · 2020 · External reference
Obesity, Dyslipidemia, and Cardiovascular Disease: A Joint Expert Review From the Obesity Medicine Association and the National Lipid Association 2024
10.1016/j.jacl.2024.04.001 · 2024 · External reference
Genetic Underpinnings of the Heterogeneous Impact of Obesity on Lipid Levels and Cardiovascular Disease
10.1186/s13073-025-01522-9 · 2025 · External reference
Recognition and Management of Persistent Chylomicronemia: A Joint Expert Clinical Consensus by the National Lipid Association and the American Society for Preventive Cardiology
10.1016/j.jacl.2025.03.012 · 2025 · External reference
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
10.1056/nejmoa2409368 · 2025 · External reference
Rates of Acute Pancreatitis and Cardiovascular Events Among Adults With Severe or Extreme Hypertriglyceridemia in Us Clinical Practice
10.1186/s12944-025-02658-8 · 2025 · External reference
Triglyceride‐Rich Lipoproteins and Their Remnants: Metabolic Insights, Role in Atherosclerotic Cardiovascular Disease, and Emerging Therapeutic Strategies‐a Consensus Statement From the European Atherosclerosis Society
10.1093/eurheartj/ehab551 · 2021 · External reference
European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO), “Easl‐Easd‐Easo Clinical Practice Guidelines on the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease (Masld)
10.1016/j.jhep.2024.04.031 · 2024 · External reference
Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review
10.3390/genes16111377 · 2025 · External reference
Triglycerides Revisited: Is Hypertriglyceridaemia a Necessary Therapeutic Target in Cardiovascular Disease?
10.1093/ehjcvp/pvad044 · 2023 · External reference
2021 Acc Expert Consensus Decision Pathway on the Management of Ascvd Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee
10.1016/j.jacc.2021.06.011 · 2021 · External reference
Metabolism of Triglyceride‐Rich Lipoproteins in Health and Dyslipidaemia
10.1038/s41569-022-00676-y · 2022 · External reference
Mechanism of Obesity‐Related Lipotoxicity and Clinical Perspective
10.1007/978-3-031-63657-8_5 · 2024 · External reference
Triglyceride‐Based Lipotoxicity in the Pathophysiology of Chronic Diseases
10.1016/j.tem.2025.07.004 · 2026 · External reference
Postprandial Triglyceride‐Rich Lipoproteins‐Induced Lysosomal Dysfunction and Impaired Autophagic Flux Contribute to Inflammation in White Adipocytes
10.1016/j.tjnut.2023.11.020 · 2024 · External reference
Targeting Insulin Resistance, Reactive Oxygen Species, Inflammation, Programmed Cell Death, Er Stress, and Mitochondrial Dysfunction for the Therapeutic Prevention of Free Fatty Acid‐Induced Vascular Endothelial Lipotoxicity
10.3390/antiox13121486 · 2024 · External reference
Triglyceride‐Rich Lipoproteins and High‐Density Lipoprotein Cholesterol in Patients at High Risk of Cardiovascular Disease: Evidence and Guidance for Management
10.1093/eurheartj/ehr112 · 2011 · External reference
Acute Pancreatitis: A Review
10.1001/jama.2020.20317 · 2021 · External reference
Hypertriglyceridemia and Acute Pancreatitis
10.1016/j.pan.2020.06.005 · 2020 · External reference
Incidence and Clinical Characteristics of Hypertriglyceridemic Acute Pancreatitis: A Retrospective Single‐Center Study
10.3748/wjg.v28.i29.3946 · 2022 · External reference
Temporal Trends in Gender, Etiology, Severity and Outcomes of Acute Pancreatitis in a Third‐Tier Chinese City From 2013 to 2021
10.1080/07853890.2024.2442073 · 2025 · External reference
Global Burden and Characterization of Hypertriglyceridemia‐Induced Acute Pancreatitis: Results From a Systematic Review and a Multi‐Center Cohort Study
10.1007/s11427-024-2900-6 · 2025 · External reference
A Systematic Review of the Epidemiology and Risk Factors for Severity and Recurrence of Hypertriglyceridemia‐Induced Acute Pancreatitis
10.1186/s12876-025-03954-4 · 2025 · External reference
Assessment of the Course of Acute Pancreatitis in the Light of Aetiology: A Systematic Review and Meta‐Analysis
10.1038/s41598-020-74943-8 · 2020 · External reference
2019 Esc/Eas Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk
10.1093/eurheartj/ehz455 · 2020 · External reference
New Therapies for Lowering Triglyceride‐Rich Lipoproteins: Jacc Focus Seminar 3/4
10.1016/j.jacc.2021.08.051 · 2021 · External reference
2025 Focused Update of the 2019 Esc/Eas Guidelines for the Management of Dyslipidaemias
2025 · External reference
Triglyceride‐Rich Lipoproteins, Remnants and Atherosclerotic Cardiovascular Disease: What We Know and What We Need to Know
10.1016/j.atherosclerosis.2025.120529 · 2025 · External reference
Role of Apolipoprotein B in the Clinical Management of Cardiovascular Risk in Adults: An Expert Clinical Consensus From the National Lipid Association
10.1016/j.jacl.2024.08.013 · 2024 · External reference
Current and Emerging Treatment Options for Hypertriglyceridemia: State‐of‐the‐Art Review
10.3390/ph18020147 · 2025 · External reference
Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
10.1056/nejmoa2402309 · 2024 · External reference
Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
10.1056/nejmoa2400201 · 2024 · External reference
Evinacumab in Severe Hypertriglyceridemia With or Without Lipoprotein Lipase Pathway Mutations: A Phase 2 Randomized Trial
10.1038/s41591-023-02222-w · 2023 · External reference
Comparison of Patients With Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia Syndrome
10.1210/clinem/dgae613 · 2025 · External reference
Lipid Management in Patients With Endocrine Disorders: An Endocrine Society Clinical Practice Guideline
10.1210/clinem/dgaa674 · 2020 · External reference
Cardiovascular Risk Reduction With Icosapent Ethyl for Hypertriglyceridemia
10.1056/nejmoa1812792 · 2019 · External reference
Hypertriglyceridemia in the Genomic Era: A New Paradigm
10.1210/er.2014-1062 · 2015 · External reference
Hypertriglyceridemia
10.1016/j.ecl.2022.02.010 · 2022 · External reference
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
10.1210/jc.2011-3213 · 2012 · External reference
Management of Hypertriglyceridemia
10.1136/bmj.m3109 · 2020 · External reference
Familial Chylomicronemia Syndrome: An Under‐Recognized Cause of Severe Hypertriglyceridaemia
10.1111/joim.13016 · 2020 · External reference
Familial Chylomicronemia Syndrome: An Expert Clinical Review From the National Lipid Association
10.1016/j.jacl.2025.03.013 · 2025 · External reference
Genetics of Hypertriglyceridemia
10.3389/fendo.2020.00455 · 2020 · External reference
A Comprehensive Update on the Chylomicronemia Syndrome
10.3389/fendo.2020.593931 · 2020 · External reference
Identification and Diagnosis of Patients With Familial Chylomicronaemia Syndrome (Fcs): Expert Panel Recommendations and Proposal of an ‘’Fcs Score
10.1016/j.atherosclerosis.2018.06.814 · 2018 · External reference
The Evolving Story of Multifactorial Chylomicronemia Syndrome
10.3389/fcvm.2022.886266 · 2022 · External reference
The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment
10.7326/m19-0203 · 2019 · External reference
Pathophysiology of Diabetic Dyslipidemia
10.5551/jat.rv17023 · 2018 · External reference
Approach to the Adult Patient With Chylomicronemia
10.1210/clinem/dgaf701 · 2026 · External reference
2024 Ksola Consensus on Secondary Dyslipidemia
10.3904/kjim.2024.156 · 2024 · External reference
Multifactorial Chylomicronemia Syndrome
10.1097/med.0000000000000846 · 2024 · External reference
Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome‐Causes, Clinical Presentation, and Therapeutic Options
10.3390/metabo13050621 · 2023 · External reference
Causes, Clinical Findings and Therapeutic Options in Chylomicronemia Syndrome, a Special Form of Hypertriglyceridemia
10.1186/s12944-022-01631-z · 2022 · External reference
Familial Chylomicronemia Syndrome (Fcs): Recent Data on Diagnosis and Treatment
10.1007/s11883-020-00885-1 · 2020 · External reference
Safety and Efficacy of Therapies for Chylomicronemia
10.1080/17512433.2022.2094768 · 2022 · External reference
Familial Chylomicronemia Syndrome: Importance of Diagnostic Vigilance
10.21037/tp-22-488 · 2022 · External reference
Genetic Determinants of Pancreatitis Risk in Hypertriglyceridemia
10.1097/mol.0000000000000962 · 2025 · External reference
Severe Hypertriglyceridemia Is Primarily Polygenic
10.1016/j.jacl.2018.10.006 · 2019 · External reference
The Genetic Basis of Hypertriglyceridemia
10.1007/s11883-021-00939-y · 2021 · External reference
Rare Variants in Triglycerides‐Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome
10.1210/clinem/dgab360 · 2021 · External reference
Hypertriglyceridemia‐Causes, Significance, and Approaches to Therapy
10.3389/fendo.2020.00616 · 2020 · External reference
Non‐Alcoholic Fatty Liver Disease in Patients With Chylomicronemia Syndromes
10.1016/j.jacl.2023.05.096 · 2023 · External reference
Familial Combined Hyperlipidemia: Myth or Reality?
10.1007/s11883-025-01289-9 · 2025 · External reference
Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities
2018 · External reference
Establishing the Relationship Between Familial Dysbetalipoproteinemia and Genetic Variants in the Apoe Gene
10.1111/cge.14185 · 2022 · External reference
Development and Validation of Clinical Criteria to Identify Familial Chylomicronemia Syndrome (Fcs) in North America
10.1016/j.jacl.2024.09.008 · 2025 · External reference
Causes and Consequences of Hypertriglyceridemia
10.3389/fendo.2020.00252 · 2020 · External reference
The Pathogenesis of Insulin Resistance: Integrating Signaling Pathways and Substrate Flux
10.1172/jci77812 · 2016 · External reference
Hypertriglyceridemia Secondary to Obesity and Diabetes
10.1016/j.bbalip.2011.10.003 · 2012 · External reference
Selective Hepatic Insulin Resistance, Vldl Overproduction, and Hypertriglyceridemia
10.1161/atvbaha.111.241463 · 2012 · External reference
Obesity and Dyslipidemia
10.1007/s11883-023-01167-2 · 2023 · External reference
Understanding Hypertriglyceridemia: Integrating Genetic Insights
10.3390/genes15020190 · 2024 · External reference
Metabolic Dysfunction‐Associated Steatotic Liver Disease: Heterogeneous Pathomechanisms and Effectiveness of Metabolism‐Based Treatment
10.1016/s2213-8587(24)00318-8 · 2025 · External reference
The Role of Insulin Resistance in Fueling Nafld Pathogenesis: From Molecular Mechanisms to Clinical Implications
10.3390/jcm11133649 · 2022 · External reference
Hepatic Selective Insulin Resistance at the Intersection of Insulin Signaling and Metabolic Dysfunction‐Associated Steatotic Liver Disease
10.1016/j.cmet.2024.04.006 · 2024 · External reference
2026 Aha/Acc/Ada/Asn Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular‐Kidney‐Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2026 · External reference
Cardiovascular‐Kidney‐Metabolic Health: A Presidential Advisory From the American Heart Association
10.1161/cir.0000000000001184 · 2023 · External reference
Hypertriglyceridemia in Chronic Kidney Disease: Pathophysiological Mechanisms, Cardiovascular Risk, and Emerging Therapeutics
10.1186/s12944-026-02862-0 · 2026 · External reference
Effects of Endocrine Disorders on Lipids and Lipoproteins
10.1016/j.beem.2022.101667 · 2023 · External reference
Lipoprotein Alterations in Endocrine Disorders—A Review of the Recent Developments in the Field
10.3389/fendo.2024.1354098 · 2024 · External reference
Lipid Abnormalities in Patients With Cushing's Disease and Its Relationship With Impaired Glucose Metabolism
10.3389/fendo.2020.600323 · 2020 · External reference
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm ‐ 2020 Executive Summary
10.4158/cs-2020-0490 · 2020 · External reference
Dietary Carbohydrates and Fats in Nonalcoholic Fatty Liver Disease
10.1038/s41575-021-00472-y · 2021 · External reference
Alcohol Effects on Hepatic Lipid Metabolism
10.1194/jlr.r119000547 · 2020 · External reference
Alcohol and Plasma Triglycerides
10.1097/mol.0b013e3283606845 · 2013 · External reference
Hypertriglyceridemic Pancreatitis: Epidemiology, Pathophysiology and Clinical Management
10.1177/2050640618755002 · 2018 · External reference
Extreme Hypertriglyceridemia: Genetic Diversity, Pancreatitis, Pregnancy, and Prevalence
10.1016/j.jacl.2018.09.007 · 2019 · External reference
A Multidisciplinary Management Model for Severe Gestational Hypertriglyceridemia: Using Plasmapheresis to Prevent Pancreatitis in Pregnancy
10.1186/s12884-025-08222-7 · 2025 · External reference
Severe Hypertriglyceridemia in Pregnancy
10.1210/jc.2012-1250 · 2012 · External reference
Aspen Lipid Injectable Emulsion Safety Recommendations, Part 1: Background and Adult Considerations
10.1002/ncp.10496 · 2020 · External reference
Espen Guidelines on Parenteral Nutrition: Pancreas
10.1016/j.clnu.2009.04.003 · 2009 · External reference
Unresolved reference
2000 · External reference
Antipsychotic‐Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
10.2337/db13-0430 · 2013 · External reference
The Wnt Signaling Pathway Effector Tcf7l2 Mediates Olanzapine‐Induced Weight Gain and Insulin Resistance
10.3389/fphar.2018.00379 · 2018 · External reference
Weight Gain and Metabolic Changes in Patients With First‐Episode Psychosis or Early‐Phase Schizophrenia Treated With Olanzapine: A Meta‐Analysis
10.1093/ijnp/pyad029 · 2023 · External reference
Role of Estrogens in the Regulation of Liver Lipid Metabolism
10.1007/978-3-319-70178-3_12 · 2017 · External reference
Dysfunction of Estrogen‐Related Receptor Alpha‐Dependent Hepatic Vldl Secretion Contributes to Sex Disparity in Nafld/Nash Development
10.7150/thno.47037 · 2020 · External reference
Metabolism of Very Low Density Lipoproteins in Rats With Isotretinoin (13‐Cis Retinoic Acid)‐Induced Hyperlipidemia
10.1016/s0022-2275(20)43204-3 · 1990 · External reference
Short‐Term Administration of Isotretinoin Elevates Plasma Triglyceride Concentrations Without Affecting Insulin Sensitivity in Healthy Humans
10.1016/j.metabol.2003.07.006 · 2004 · External reference
The Effect of Thiazide Diuretics on Blood Lipid Profile in Hypertensive Adults: A Meta‐Analysis of Randomized Controlled Trials
2018 · External reference
Thiazide‐Induced Disturbances in Carbohydrate, Lipid, and Potassium Metabolism
10.1016/0002-8703(83)90124-2 · 1983 · External reference
10.1186/2045-3701-2-19 · 2012 · Admitted local publication
Angiopoietin‐Like 4 (Angptl4, Fasting‐Induced Adipose Factor) Is a Direct Glucocorticoid Receptor Target and Participates in Glucocorticoid‐Regulated Triglyceride Metabolism
10.1074/jbc.m109.025452 · 2009 · External reference
Management of Dyslipidemia in Adult Solid Organ Transplant Recipients
10.1016/j.jacl.2019.01.011 · 2019 · External reference
Effects of Sirolimus on Plasma Lipids, Lipoprotein Levels, and Fatty Acid Metabolism in Renal Transplant Patients
10.1194/jlr.m100392-jlr200 · 2002 · External reference
Interferon Alpha Induces Disorder of Lipid Metabolism by Lowering Postheparin Lipases and Cholesteryl Ester Transfer Protein Activities in Patients With Chronic Hepatitis C
10.1002/hep.510250632 · 1997 · External reference
The Role of Protease Inhibitors in the Pathogenesis of Hiv‐Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications
10.1177/0192623308327119 · 2009 · External reference
Dyslipidemia in the Era of Hiv Protease Inhibitors
10.1053/pcad.2003.3 · 2003 · External reference
Severe Hypertriglyceridaemia During Therapy for Childhood Acute Lymphoblastic Leukaemia
10.1016/j.ejca.2014.06.023 · 2014 · External reference
Asparaginase Formulation Impacts Hypertriglyceridemia During Therapy for Acute Lymphoblastic Leukemia
10.1002/pbc.28040 · 2020 · External reference
Triglyceride Concentrations and Their Relationship to Sedation Choice and Outcomes in Mechanically Ventilated Patients Receiving Propofol
10.1513/annalsats.202205-403oc · 2023 · External reference
Unresolved reference
2026 · External reference
Hypertriglyceridemia‐Related Pancreatitis in Patients With Type 2 Diabetes: Links and Risks
10.2147/dmso.s188856 · 2019 · External reference
Severe Hypertriglyceridemia: Existing and Emerging Therapies
10.1016/j.pharmthera.2023.108544 · 2023 · External reference
Hypertriglyceridemia‐Associated Drug‐Induced Acute Pancreatitis
10.1097/mpa.0000000000001190 · 2019 · External reference
Triglyceride‐Rich Lipoproteins and Inflammation: Independent and Synergistic Roles in Cardiovascular Disease
10.1007/s11883-026-01393-4 · 2026 · External reference
2026 Acc/Aha/Aacvpr/Abc/Acpm/Ada/Ags/Apha/Aspc/Nla/Pcna Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2025.11.016 · 2026 · External reference
Triglyceride‐Rich Lipoprotein Remnants, Low‐Density Lipoproteins, and Risk of Coronary Heart Disease: A Uk Biobank Study
10.1093/eurheartj/ehad337 · 2023 · External reference
From Lipotoxicity to Pan‐Lipotoxicity
10.1038/s41421-025-00787-z · 2025 · External reference
Comprehensive Review on the Pathogenesis of Hypertriglyceridaemia‐Associated Acute Pancreatitis
10.1080/07853890.2023.2265939 · 2023 · External reference
Mechanisms Linking Hypertriglyceridemia to Acute Pancreatitis
10.1111/apha.13916 · 2023 · External reference
Intestinal Barrier Damage, Systemic Inflammatory Response Syndrome, and Acute Lung Injury: A Troublesome Trio for Acute Pancreatitis
10.1016/j.biopha.2020.110770 · 2020 · External reference
Gut Microbiota Aggravates Neutrophil Extracellular Traps‐Induced Pancreatic Injury in Hypertriglyceridemic Pancreatitis
10.1038/s41467-023-41950-y · 2023 · External reference
Lipoprotein Lipase and Its Regulators: An Unfolding Story
10.1016/j.tem.2020.11.005 · 2021 · External reference
Angiopoietin‐Like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride‐Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies
10.3390/jcm13175229 · 2024 · External reference
Triglycerides and Heart Disease: Still a Hypothesis?
10.1161/atvbaha.111.226100 · 2011 · External reference
New Insights Into the Pathophysiology of Dyslipidemia in Type 2 Diabetes
10.1016/j.atherosclerosis.2015.01.039 · 2015 · External reference
Sources of Fatty Acids Stored in Liver and Secreted via Lipoproteins in Patients With Nonalcoholic Fatty Liver Disease
10.1172/jci23621 · 2005 · External reference
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
10.1007/s10620-016-4054-0 · 2016 · External reference
Metabolic‐Associated Fatty Liver Disease and Lipoprotein Metabolism
10.1016/j.molmet.2021.101238 · 2021 · External reference
Mechanisms for Insulin Resistance: Common Threads and Missing Links
10.1016/j.cell.2012.02.017 · 2012 · External reference
The Role of Hepatic Lipids in Hepatic Insulin Resistance and Type 2 Diabetes
10.1038/nature13478 · 2014 · External reference
Selective versus Total Insulin Resistance: A Pathogenic Paradox
10.1016/j.cmet.2007.12.009 · 2008 · External reference
A Unified Model for Regulating Lipoprotein Lipase Activity
10.1016/j.tem.2024.02.016 · 2024 · External reference
Molecular Genetic Testing and Measurement of Levels of Gpihbp1 Autoantibodies in Patients With Severe Hypertriglyceridemia: The Importance of Identifying the Underlying Cause of Hypertriglyceridemia
10.1016/j.jacl.2023.11.002 · 2024 · External reference
Mutations in Lpl, Apoc2, Apoa5, Gpihbp1 and Lmf1 in Patients With Severe Hypertriglyceridaemia
10.1111/j.1365-2796.2012.02516.x · 2012 · External reference
Apoc‐Iii: A Gatekeeper in Controlling Triglyceride Metabolism
10.1007/s11883-023-01080-8 · 2023 · External reference
Apolipoprotein C3: Form Begets Function
10.1016/j.jlr.2023.100475 · 2024 · External reference
Drug‐Target Mendelian Randomization Analysis Supports Lowering Plasma Angptl3, Angptl4, and Apoc3 Levels as Strategies for Reducing Cardiovascular Disease Risk
10.1093/ehjopen/oeae035 · 2024 · External reference
Molecular Mechanism of Lipotoxicity as an Interesting Aspect in the Development of Pathological States‐Current View of Knowledge
10.3390/cells11050844 · 2022 · External reference
Pathogenesis of Masld and Mash—Role of Insulin Resistance and Lipotoxicity
10.1111/apt.17930 · 2024 · External reference
Free Fatty Acid Receptors in Health and Disease
10.1152/physrev.00041.2018 · 2020 · External reference
Acute Pancreatitis: Mechanisms and Therapeutic Approaches
10.1038/s41392-025-02394-6 · 2026 · External reference
Triglyceride‐Rich Lipoproteins, Remnant‐Cholesterol, and Atherosclerotic Cardiovascular Disease
10.1097/mol.0000000000000875 · 2023 · External reference
The Crosstalk Between Mitochondrial Dysfunction and Fatty Acid Metabolism in Heart Failure: Mechanisms and Therapeutic Strategies
10.3389/fphar.2025.1679085 · 2025 · External reference
Fatty Acids Decrease Mitochondrial Generation of Reactive Oxygen Species at the Reverse Electron Transport but Increase It at the Forward Transport
10.1016/j.bbabio.2007.04.005 · 2007 · External reference
Induction of Hyperlipidemic Pancreatitis by Different Fatty Acids: A Narrative Review
2025 · External reference
Mitochondrial Dysfunction in Pancreatic Acinar Cells: Mechanisms and Therapeutic Strategies in Acute Pancreatitis
10.3389/fimmu.2024.1503087 · 2024 · External reference
Blocking Cirp Protects Against Acute Pancreatitis by Improving Mitochondrial Function and Suppressing Pyroptosis in Acinar Cells
10.1038/s41420-024-01923-6 · 2024 · External reference
Remnant Cholesterol Trajectory and Subclinical Arteriosclerosis: A 10‐Year Longitudinal Study of Chinese Adults
10.1038/s41598-024-59173-6 · 2024 · External reference
Beyond Ldl‐C: Unravelling the Residual Atherosclerotic Cardiovascular Disease Risk Landscape‐Focus on Hypertriglyceridaemia
10.3389/fcvm.2024.1389106 · 2024 · External reference
Elevated Blood Remnant Cholesterol and Triglycerides Are Causally Related to the Risks of Cardiometabolic Multimorbidity
10.1038/s41467-024-46686-x · 2024 · External reference
Bidirectional Crosstalk Between Er Stress and Lipid Metabolism: From Proteostasis to Tumor Adaptation
10.1038/s41420-025-02878-y · 2025 · External reference
Endoplasmic Reticulum Stress as a Driver and Therapeutic Target for Kidney Disease
10.1038/s41581-025-00938-1 · 2025 · External reference
Effect of Saturated Stearic Acid on Map Kinase and Er Stress Signaling Pathways During Apoptosis Induction in Human Pancreatic Β‐Cells Is Inhibited by Unsaturated Oleic Acid
10.3390/ijms18112313 · 2017 · External reference
Mechanisms, Regulation and Functions of the Unfolded Protein Response
10.1038/s41580-020-0250-z · 2020 · External reference
Metabolic Disturbances in Acute Pancreatitis: Mechanisms and Therapeutic Implications
10.3389/fendo.2025.1579457 · 2025 · External reference
A Microrna Checkpoint for Ca(2+) Signaling and Overload in Acute Pancreatitis
10.1016/j.ymthe.2022.01.033 · 2022 · External reference
The Role of Ca(2+) Signalling in the Pathology of Exocrine Pancreas
10.1016/j.ceca.2023.102740 · 2023 · External reference
Caerulein‐Induced Nf‐Kappab/Rel Activation Requires both Ca2+ and Protein Kinase C as Messengers
10.1152/ajpgi.1999.277.3.g678 · 1999 · External reference
Signaling Pathways Involved in Acute Pancreatitis
10.2147/jir.s485804 · 2025 · External reference
Sphingosine 1‐Phosphate Receptor 2 Mediated Early Stages of Pancreatic and Systemic Inflammatory Responses via Nf‐Kappa B Activation in Acute Pancreatitis
10.1186/s12964-022-00971-8 · 2022 · External reference
Ferroptosis: An Iron‐Dependent Form of Nonapoptotic Cell Death
10.1016/j.cell.2012.03.042 · 2012 · External reference
Ferroptosis Exacerbates Hyperlipidemic Acute Pancreatitis by Enhancing Lipid Peroxidation and Modulating the Immune Microenvironment
10.1038/s41420-024-02007-1 · 2024 · External reference
Autophagy in Human Diseases
10.1056/nejmra2022774 · 2020 · External reference
Regulation of Autophagy by Perilysosomal Calcium: A New Player in Β‐Cell Lipotoxicity
10.1038/s12276-024-01161-x · 2024 · External reference
Autolysosomal Dysfunction in Obesity‐Induced Metabolic Inflammation and Related Disorders
10.1007/s13679-025-00638-8 · 2025 · External reference
The Interplay Involving Oxidative Stress and Autophagy: Mechanisms, Implications, and Therapeutic Opportunities
10.1016/j.yexmp.2025.104989 · 2025 · External reference
Rapamycin Alleviates Hypertriglyceridemia‐Related Acute Pancreatitis via Restoring Autophagy Flux and Inhibiting Endoplasmic Reticulum Stress
10.1007/s10753-020-01228-7 · 2020 · External reference
New Insights Into Acute Pancreatitis
10.1038/s41575-019-0158-2 · 2019 · External reference
Association Between Autophagy and Acute Pancreatitis
10.3389/fgene.2023.998035 · 2023 · External reference
Autophagy Regulates Cholesterol Efflux From Macrophage Foam Cells via Lysosomal Acid Lipase
10.1016/j.cmet.2011.03.023 · 2011 · External reference
The Roles of Macrophage Autophagy in Atherosclerosis
10.1038/aps.2015.87 · 2016 · External reference
A Role for Lipophagy in Atherosclerosis
10.1038/s41569-023-00885-z · 2023 · External reference
Neutrophil Extracellular Traps Mediate M(6)a Modification and Regulates Sepsis‐Associated Acute Lung Injury by Activating Ferroptosis in Alveolar Epithelial Cells
10.7150/ijbs.69141 · 2022 · External reference
Recent Advances in the Role of Neutrophils and Neutrophil Extracellular Traps in Acute Pancreatitis
10.1007/s10238-023-01180-4 · 2023 · External reference
High‐Mobility Group Box Protein‐1 Induces Acute Pancreatitis Through Activation of Neutrophil Extracellular Trap and Subsequent Production of Il‐1β
10.1016/j.lfs.2021.119231 · 2021 · External reference
Toll‐Like Receptor 4 in Pancreatic Damage and Immune Infiltration in Acute Pancreatitis
10.3389/fimmu.2024.1362727 · 2024 · External reference
Neutrophil Extracellular Traps Participate in Cardiovascular Diseases: Recent Experimental and Clinical Insights
10.1161/circresaha.120.315931 · 2020 · External reference
Neutrophil Extracellular Traps Induce Endothelial Cell Activation and Tissue Factor Production Through Interleukin‐1α and Cathepsin G
10.1161/atvbaha.118.311150 · 2018 · External reference
Effects of Lipoproteins on Plasma Viscosity
10.1016/0021-9150(81)90107-6 · 1981 · External reference
Hypoxic Functional Regulation Pathways in the Gi Tract: Focus on the Hif‐1α and Microbiota's Crosstalk
10.1093/ibd/izae046 · 2024 · External reference
Hypoxia, Hypoxia‐Inducible Factors and Inflammatory Bowel Diseases
10.1093/gastro/goae030 · 2024 · External reference
Molecular Mechanisms, Dynamic Lesions, and Therapeutic Targets in Intestinal Ischemia‐Reperfusion Injury: A Systematic Review
10.3390/ijms27041763 · 2026 · External reference
Dysbiosis of Intestinal Microbiota and Decreased Antimicrobial Peptide Level in Paneth Cells During Hypertriglyceridemia‐Related Acute Necrotizing Pancreatitis in Rats
10.3389/fmicb.2017.00776 · 2017 · External reference
Gut Microbiota and Obesity
10.1007/s00018-015-2061-5 · 2016 · External reference
Short‐Chain Fatty Acid Butyrate, a Breast Milk Metabolite, Enhances Immature Intestinal Barrier Function Genes in Response to Inflammation in Vitro and in Vivo
10.1152/ajpgi.00279.2020 · 2021 · External reference
The Importance of Microbiota and Fecal Microbiota Transplantation in Pancreatic Disorders
10.3390/diagnostics14090861 · 2024 · External reference
Metabolic Endotoxemia: From the Gut to Neurodegeneration
10.3390/ijms25137006 · 2024 · External reference
Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions
10.3389/fimmu.2020.594150 · 2020 · External reference
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
10.2337/db06-1491 · 2007 · External reference
Toll‐Like Receptor 4 (Tlr4): New Insight Immune and Aging
10.1186/s12979-023-00383-3 · 2023 · External reference
Gut‐Derived Low‐Grade Endotoxaemia, Atherothrombosis and Cardiovascular Disease
10.1038/s41569-022-00737-2 · 2023 · External reference
Intestinal Gstpi Deficiency Exacerbates the Severity of Experimental Hyperlipidemic Acute Pancreatitis
10.1016/j.intimp.2024.112363 · 2024 · External reference
Activated Regulatory T‐Cells Promote Duodenal Bacterial Translocation Into Necrotic Areas in Severe Acute Pancreatitis
10.1136/gutjnl-2022-327448 · 2023 · External reference
The Th17/Treg Cell Balance: A Gut Microbiota‐Modulated Story
10.3390/microorganisms7120583 · 2019 · External reference
The Effects of Microbiota‐Derived Short‐Chain Fatty Acids on T Lymphocytes: From Autoimmune Diseases to Cancer
10.1016/j.seminoncol.2025.152398 · 2025 · External reference
Are We There Yet? Gut Microbiota for Cancer Diagnosis, Prognosis and Treatment
10.1016/j.seminoncol.2025.152376 · 2025 · External reference
Nf‐Κb in Biology and Targeted Therapy: New Insights and Translational Implications
10.1038/s41392-024-01757-9 · 2024 · External reference
Nf‐Κb: Blending Metabolism, Immunity, and Inflammation
10.1016/j.it.2022.07.004 · 2022 · External reference
Deciphering the Tlr4 and Nlrp3 Inflammasome Crosstalk for Therapeutic Restoration of Intestinal and Systemic Immunity
10.1007/s10620-025-09655-y · 2026 · External reference
Hypertriglyceridemia: Molecular and Genetic Landscapes
10.3390/ijms25126364 · 2024 · External reference
Current Knowledge of Hypertriglyceridemic Pancreatitis
10.1016/j.ejim.2014.08.008 · 2014 · External reference
Severe Hypertriglyceridemia and Pancreatitis: Presentation and Management
10.1097/mol.0b013e3283319a1d · 2009 · External reference
Low‐Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence From Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement From the European Atherosclerosis Society Consensus Panel
10.1093/eurheartj/ehx144 · 2017 · External reference
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
10.1056/nejmoa1715944 · 2019 · External reference
Angiopoietin‐Like 3 in Lipoprotein Metabolism
10.1038/nrendo.2017.119 · 2017 · External reference
Fasting Compared With Nonfasting Triglycerides and Risk of Cardiovascular Events in Women
10.1001/jama.298.3.309 · 2007 · External reference
Insulin Resistance, and the Metabolic Syndrome
10.1016/s0002-9149(99)00211-8 · 1999 · External reference
The Complex Metabolic Mechanisms Relating Obesity to Hypertriglyceridemia
10.1161/atvbaha.111.233049 · 2011 · External reference
Genetics and Causality of Triglyceride‐Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
10.1016/j.jacc.2014.09.042 · 2014 · External reference
Triglyceride‐Rich Lipoproteins and Atherosclerotic Cardiovascular Disease New Insights From Epidemiology, Genetics, and Biology
10.1161/circresaha.115.306249 · 2016 · External reference
Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Lipid Lowering Arm
10.1001/jamainternmed.2019.0392 · 2019 · External reference
Triglycerides and Cardiovascular Disease
10.1016/s0140-6736(14)61177-6 · 2014 · External reference
Impact of Hypertriglyceridaemia on Cardiovascular Mortality According to Low‐Density Lipoprotein Cholesterol in a 15.6‐Million Population
10.1093/eurjpc/zwad330 · 2024 · External reference
Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State
10.1373/clinchem.2015.241752 · 2015 · External reference
Non‐Remnant Triglyceride‐Rich Lipoproteins due to Lipoprotein Lipase Deficiency Increase Atherosclerosis in Mice
10.1038/s41467-025-68193-3 · 2026 · External reference
Apolipoprotein B‐Containing Lipoproteins in Atherogenesis
10.1038/s41569-024-01111-0 · 2025 · External reference
Small Remnants versus Large Triglyceride‐Rich Lipoproteins in Risk of Atherosclerotic Cardiovascular Disease
10.1093/clinchem/hvae222 · 2025 · External reference
Macrophages Take up Vldl‐Sized Emulsion Particles Through Caveolae‐Mediated Endocytosis and Excrete Part of the Internalized Triglycerides as Fatty Acids
10.1371/journal.pbio.3001516 · 2022 · External reference
Remnant Lipoprotein Particles and Cardiovascular Disease Risk
10.1016/j.beem.2022.101682 · 2023 · External reference
Independent Causal Effect of Remnant Cholesterol on Atherosclerotic Cardiovascular Outcomes: A Mendelian Randomization Study
10.1161/atvbaha.123.319297 · 2023 · External reference
Loss‐of‐Function Mutations in Apoc3, Triglycerides, and Coronary Disease
10.1056/nejmoa1307095 · 2014 · External reference
Inactivating Variants in Angptl4 and Risk of Coronary Artery Disease
10.1056/nejmoa1510926 · 2016 · External reference
Genetic and Pharmacologic Inactivation of Angptl3 and Cardiovascular Disease
10.1056/nejmoa1612790 · 2017 · External reference
Remnant Cholesterol Concentrations Best Explain the Cardiovascular Benefit of Apoc3 Genetic Inhibition: A Drug Target Mendelian Randomization Study
10.1093/ehjopen/oeaf018 · 2025 · External reference
Association of Triglyceride‐Lowering Variants and Ldl‐C‐Lowering Variants With Risk of Coronary Heart Disease
10.1001/jama.2018.20045 · 2019 · External reference
Quantifying Triglyceride‐Rich Lipoprotein Atherogenicity, Associations With Inflammation, and Implications for Risk Assessment Using Non‐Hdl Cholesterol
10.1016/j.jacc.2024.07.034 · 2024 · External reference
Remnant Cholesterol as a Residual Risk in Atherosclerotic Cardiovascular Disease Patients Under Statin‐Based Lipid‐Lowering Therapy: A Post Hoc Analysis of the Racing Trial
10.1016/j.jacl.2024.07.005 · 2024 · External reference
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
10.1161/circulationaha.121.057807 · 2022 · External reference
Elevated Remnant Cholesterol Causes both Low‐Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low‐Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation
10.1161/circulationaha.113.003008 · 2013 · External reference
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid‐Lowering Therapeutic Classes: A Systematic Review and Meta‐Regression Analysis of Randomized Controlled Trials
10.1161/circulationaha.119.041998 · 2019 · External reference
Hypertriglyceridaemia‐Associated Acute Pancreatitis: Risk Stratification, Drivers, and Prevention of Recurrence
10.3390/diseases14020047 · 2026 · External reference
Prevalence, Severity and Management of Hypertriglyceridemia‐Associated Pancreatitis; a 7‐Year Retrospective Cohort Study at Canadian Quaternary Care Hospitals
10.1016/j.jacl.2022.05.064 · 2022 · External reference
Clinical Features and Outcomes of Hypertriglyceridemia‐Induced Acute Pancreatitis: Propensity Score Matching Analysis From a Prospective Acute Pancreatitis Registry
10.1016/j.pan.2020.03.013 · 2020 · External reference
Prevention and Treatment of Hypertriglyceridemia‐Mediated Acute Pancreatitis: A Narrative Review
10.1016/j.ejim.2025.106648 · 2026 · External reference
Issues in Hypertriglyceridemic Pancreatitis: An Update
10.1097/01.mcg.0000436438.60145.5a · 2014 · External reference
Nonfasting Mild‐to‐Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis
10.1001/jamainternmed.2016.6875 · 2016 · External reference
A Systematic Review of the Epidemiology, Pathophysiology and Current Management of Hyperlipidaemic Pancreatitis
10.1016/j.clnu.2017.09.028 · 2018 · External reference
Gluttony, Sloth and the Metabolic Syndrome: A Roadmap to Lipotoxicity
10.1016/j.tem.2010.01.009 · 2010 · External reference
Acute Pancreatitis: A Multifaceted Set of Organelle and Cellular Interactions
10.1053/j.gastro.2018.11.082 · 2019 · External reference
Hypertriglyceridemia Screening in Acute Pancreatitis: Diagnostic Blind Spot in Clinical Routine
10.1007/s10620-025-09366-4 · 2026 · External reference
The Role of Apheresis and Insulin Therapy in Hypertriglyceridemic Acute Pancreatitis‐a Concise Review
10.1186/s12876-023-02957-3 · 2023 · External reference
Recurrence of Hypertriglyceridemia‐Associated Acute Pancreatitis: A Multicenter, Prospective Cohort Study
10.1016/j.ejim.2024.03.022 · 2024 · External reference
Serum Triglyceride Levels Are Associated With Recurrence in Patients With Acute Hypertriglyceridemic Pancreatitis
10.3389/fmed.2023.1079637 · 2023 · External reference
Recurrence Rates and Risk Factors for Recurrence After First Episode of Acute Pancreatitis: A Systematic Review and Meta‐Analysis
10.1016/j.ejim.2023.06.006 · 2023 · External reference
Lipid Metabolism for Predicting the Recurrence of Hypertriglyceridemic Acute Pancreatitis
10.1016/j.heliyon.2023.e17443 · 2023 · External reference
Risk of Recurrent Pancreatitis and Progression to Chronic Pancreatitis After a First Episode of Acute Pancreatitis
10.1016/j.cgh.2015.12.040 · 2016 · External reference
Frequency of Progression From Acute to Chronic Pancreatitis and Risk Factors: A Meta‐Analysis
10.1053/j.gastro.2015.07.066 · 2015 · External reference
Risk of and Factors Influencing the Progression From Acute to Recurrent Acute to Chronic Pancreatitis
10.1016/j.pan.2025.04.004 · 2025 · External reference
Hepatic Glucose Metabolism in the Steatotic Liver
10.1038/s41575-023-00888-8 · 2024 · External reference
The Interplay Between the Muscle and Liver in the Regulation of Glucolipid Metabolism
10.1093/jmcb/mjad073 · 2024 · External reference
Hypertriglyceridaemia: An Update
10.1136/jclinpath-2021-207719 · 2022 · External reference
Liver Insulinization as a Driver of Triglyceride Dysmetabolism
10.1038/s42255-023-00843-6 · 2023 · External reference
Molecular Regulation and Therapeutic Targeting of Vldl Production in Cardiometabolic Disease
10.1016/j.jcmgh.2024.101409 · 2025 · External reference
Updated Mechanisms of Masld Pathogenesis
10.1186/s12944-024-02108-x · 2024 · External reference
Restoring Metabolic Flexibility: Targeting Organelle Interaction Networks in the Pathogenesis and Therapy of Masld
10.3389/fcell.2025.1718799 · 2025 · External reference
Loss of Tmem55b Modulates Lipid Metabolism Through Dysregulated Lipophagy and Mitochondrial Function
10.1038/s41419-025-08210-x · 2026 · External reference
Mechanisms and Therapeutic Targets of Mitochondria in the Progression of Metabolic Dysfunction‐Associated Steatotic Liver Disease
10.1016/j.aohep.2024.101774 · 2025 · External reference
Lipid Abnormality in Diabetic Kidney Disease and Potential Treatment Advancements
10.3389/fendo.2025.1503711 · 2025 · External reference
Lipoproteins and Fatty Acids in Chronic Kidney Disease: Molecular and Metabolic Alterations
10.1038/s41581-021-00423-5 · 2021 · External reference
The Vicious Circle of Chronic Kidney Disease and Hypertriglyceridemia: What Is First, the Hen or the Egg?
10.1016/j.atherosclerosis.2025.119146 · 2025 · External reference
Remnant Cholesterol and the Risk of Aortic Valve Calcium Progression: Insights From the Mesa Study
10.1186/s12933-023-02081-2 · 2024 · External reference
Remnant Cholesterol and Risk of Aortic Aneurysm and Dissection: A Prospective Cohort Study From the Uk Biobank Study and Mendelian Randomization Analysis
10.1186/s12944-025-02466-0 · 2025 · External reference
Abdominal Aortic Aneurysm and Cardiometabolic Traits Share Strong Genetic Susceptibility to Lipid Metabolism and Inflammation
10.1038/s41467-024-49921-7 · 2024 · External reference
Course of Pregnancies and Occurrence of Acute Pancreatitis in Women With Chylomicronemia
10.1210/clinem/dgaf409 · 2026 · External reference
Pre‐Eclampsia, Gestational Hypertension, and Lipid Levels During Pregnancy: A Systematic Review and Meta‐Analysis
10.1007/s00404-025-08052-0 · 2025 · External reference
Maternal Hypertriglyceridemia in Gestational Diabetes: A New Risk Factor?
10.3390/nu16111577 · 2024 · External reference
Genetic Insights Into Causal Effects of Lipids and Lipid‐Modifying Targets on Calcific Aortic Valve Stenosis: A Mendelian Randomized Study
10.1038/s41598-025-15525-4 · 2025 · External reference
Lipid‐Lowering Therapies for Aortic Stenosis: A Drug‐Target Mendelian Randomization Study
10.1093/ehjcvp/pvae092 · 2025 · External reference
Nonfasting Lipid Testing: The New Standard for Cardiovascular Risk Assessment
10.1503/cmaj.180804 · 2018 · External reference
Nonfasting versus Fasting Lipid Profile for Cardiovascular Risk Prediction
10.1016/j.pathol.2018.09.062 · 2019 · External reference
Unraveling the Controversy Between Fasting and Nonfasting Lipid Testing in a Normal Population: A Systematic Review and Meta‐Analysis of 244,665 Participants
10.1186/s12944-024-02169-y · 2024 · External reference
A Third of Nonfasting Plasma Cholesterol Is in Remnant Lipoproteins: Lipoprotein Subclass Profiling in 9293 Individuals
10.1016/j.atherosclerosis.2019.05.011 · 2019 · External reference
Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women
10.1001/jama.298.3.299 · 2007 · External reference
Elevated Remnant Cholesterol, Plasma Triglycerides, and Cardiovascular and Non‐Cardiovascular Mortality
10.1093/eurheartj/ehac822 · 2023 · External reference
Worldwide Increasing Use of Nonfasting Rather Than Fasting Lipid Profiles
10.1093/clinchem/hvae046 · 2024 · External reference
Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cut‐Points‐a Joint Consensus Statement From the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
10.1373/clinchem.2016.258897 · 2016 · External reference
Is It Time to Abandon Fasting for Routine Lipid Testing?
10.3949/ccjm.84a.16135 · 2017 · External reference
Lipid Measurements in the Management of Cardiovascular Diseases: Practical Recommendations a Scientific Statement From the National Lipid Association Writing Group
10.1016/j.jacl.2021.09.046 · 2021 · External reference
Fasting, Non‐Fasting and Postprandial Triglycerides for Screening Cardiometabolic Risk
10.1017/jns.2021.73 · 2021 · External reference
Is Hypertriglyceridemia a Reliable Indicator of Cholesterol‐Depleted Apo B Particles?
10.1016/j.jacl.2023.05.093 · 2023 · External reference
Triglyceride‐Lowering Therapies in Hypertriglyceridemia‐Associated Acute Pancreatitis in China: A Multicentre Prospective Cohort Study
10.1186/s12916-024-03755-8 · 2024 · External reference
Diagnosis, Evaluation, and Management of Severe Hypertriglyceridemia
10.1007/s12170-025-00758-9 · 2025 · External reference
Residual Lipid Risk in Atherosclerotic Cardiovascular Disease
10.1093/eurheartj/ehag087 · 2026 · External reference
Triglycerides and Cardiovascular Risk: Getting to the Heart of the Matter
10.1016/j.jacc.2024.07.027 · 2024 · External reference
Estimation of the Concentration of Low‐Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge
10.1093/clinchem/18.6.499 · 1972 · External reference
Comparison of a Novel Method vs the Friedewald Equation for Estimating Low‐Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile
10.1001/jama.2013.280532 · 2013 · External reference
Discordance Among Apob, Non‐High‐Density Lipoprotein Cholesterol, and Triglycerides: Implications for Cardiovascular Prevention
10.1093/eurheartj/ehae258 · 2024 · External reference
New Joint Consensus Initiative on Quantifying Atherogenic Lipoproteins
10.1016/j.atherosclerosis.2018.08.037 · 2018 · External reference
Ldl‐C Calculated by Friedewald, Martin‐Hopkins, or Nih Equation 2 versus Beta‐Quantification: Pooled Alirocumab Trials
10.1016/j.jlr.2021.100148 · 2022 · External reference
Unresolved reference
2024 · External reference
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics: Implications for Precision Medicine‐Brief Report
10.1161/atvbaha.122.318445 · 2022 · External reference
Familial Chylomicronemia Syndrome: A Rare but Devastating Autosomal Recessive Disorder Characterized by Refractory Hypertriglyceridemia and Recurrent Pancreatitis
10.1016/j.tcm.2019.03.001 · 2020 · External reference
Chylomicronemia: Differences Between Familial Chylomicronemia Syndrome and Multifactorial Chylomicronemia
10.1016/j.atherosclerosis.2018.12.019 · 2019 · External reference
Novel Therapeutics for Familial Chylomicronemia Syndrome
10.1007/s11883-025-01295-x · 2025 · External reference
Unresolved reference
2024 · External reference
Is Genetic Testing in Hypertriglyceridemia Useful?
10.1161/atvbaha.122.318621 · 2022 · External reference
Polygenic Scores for Dyslipidemia: The Emerging Genomic Model of Plasma Lipoprotein Trait Inheritance
10.1097/mol.0000000000000737 · 2021 · External reference
Six Years' Experience With Lipidseq: Clinical and Research Learnings From a Hybrid, Targeted Sequencing Panel for Dyslipidemias
10.1186/s12920-020-0669-2 · 2020 · External reference
Pathogenicity Assessment of Genetic Variants Identified in Patients With Severe Hypertriglyceridemia: Novel Cases of Familial Chylomicronemia Syndrome From the Dyslipidemia Registry of the Spanish Atherosclerosis Society
10.1016/j.gim.2025.101365 · 2025 · External reference
Hypertriglyceridemia as a Risk Factor for Complications of Acute Pancreatitis and the Development of a Severity Prediction Model
10.1016/j.hpb.2023.05.006 · 2023 · External reference
Ultra‐Early Indicators of Acute Hypertriglyceridemic Pancreatitis May Influence Treatment Decision‐Making
10.1038/s41598-025-85847-w · 2025 · External reference
A Review of Acute Pancreatitis
10.1001/jama.2021.6012 · 2021 · External reference
Retrospective Study of Patients With Acute Pancreatitis: Is Serum Amylase Still Required?
10.1136/bmjopen-2012-001471 · 2012 · External reference
Lipase or Amylase for the Diagnosis of Acute Pancreatitis?
10.1016/j.clinbiochem.2017.07.003 · 2017 · External reference
Evaluating Interference of Lipemia on Routine Clinical Biochemical Tests
10.1055/s-0042-1758664 · 2023 · External reference
Lipemia: Causes, Interference Mechanisms, Detection and Management
10.11613/bm.2014.008 · 2014 · External reference
Methods to Reduce Lipemic Interference in Clinical Chemistry Tests: A Systematic Review and Recommendations
2022 · External reference
Prediction of Severe Hypertriglyceridemia‐Associated Acute Pancreatitis Using a Nomogram Based on Ct Findings and Blood Biomarkers
10.1097/md.0000000000037911 · 2024 · External reference
Evaluation of the Bisap Scoring System in Prognostication of Acute Pancreatitis—A Prospective Observational Study
10.1016/j.ijsu.2018.04.026 · 2018 · External reference
Diagnosis and Management of Acute Pancreatitis
10.1053/j.gastro.2024.02.052 · 2024 · External reference
Acute Pancreatitis: A Review of Diagnosis, Severity Prediction and Prognosis Assessment From Imaging Technology, Scoring System and Artificial Intelligence
10.3748/wjg.v29.i37.5268 · 2023 · External reference
Establishment and Validation of Early Prediction Model for Hypertriglyceridemic Severe Acute Pancreatitis
10.1186/s12944-023-01984-z · 2023 · External reference
Automated Machine Learning for the Early Prediction of the Severity of Acute Pancreatitis in Hospitals
10.3389/fcimb.2022.886935 · 2022 · External reference
Construction of a Predictive Model for Severe Hypertriglyceridemia‐Associated Acute Pancreatitis Using Machine Learning
10.62347/pcir2698 · 2025 · External reference
Advances in the Clinical Application of Machine Learning in Acute Pancreatitis: A Review
10.3389/fmed.2024.1487271 · 2024 · External reference
Predictive Value of Machine Learning for the Severity of Acute Pancreatitis: A Systematic Review and Meta‐Analysis
10.1016/j.heliyon.2024.e29603 · 2024 · External reference
Predicting Acute Pancreatitis Severity With Enhanced Computed Tomography Scans Using Convolutional Neural Networks
10.1038/s41598-023-44828-7 · 2023 · External reference
A Systematic Review of Machine Learning‐Based Prognostic Models for Acute Pancreatitis: Towards Improving Methods and Reporting Quality
10.1371/journal.pmed.1004432 · 2025 · External reference
Critical Appraisal of Machine Learning Prognostic Models for Acute Pancreatitis: Protocol for a Systematic Review
10.1186/s41512-024-00169-1 · 2024 · External reference
Tripod+Ai Statement: Updated Guidance for Reporting Clinical Prediction Models That Use Regression or Machine Learning Methods
10.1136/bmj-2023-078378 · 2024 · External reference
The Polygenic Nature of Hypertriglyceridaemia: Implications for Definition, Diagnosis, and Management
10.1016/s2213-8587(13)70191-8 · 2014 · External reference
The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk
10.1210/er.2018-00184 · 2019 · External reference
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
10.1016/j.jacc.2012.08.1026 · 2013 · External reference
The Dawn of a New Era of Targeted Lipid‐Lowering Therapies
10.1093/eurheartj/ehab841 · 2022 · External reference
Addressing Dyslipidemic Risk Beyond Ldl‐Cholesterol
10.1172/jci148559 · 2022 · External reference
Fluid Resuscitation in the Early Management of Acute Pancreatitis—Evidence From a Systematic Review and Meta‐Analysis
10.1016/j.hpb.2023.08.013 · 2023 · External reference
Comparison of Fluid Resuscitation With Lactate Ringer's versus Normal Saline in Acute Pancreatitis: An Updated Meta‐Analysis
10.1007/s10620-023-08187-7 · 2024 · External reference
Lactated Ringer's Solution Reduces Severity, Mortality, Systemic and Local Complications in Acute Pancreatitis: A Systematic Review and Meta‐Analysis
10.3390/biomedicines11020321 · 2023 · External reference
American Gastroenterological Association Institute Guideline on initial Management of Acute Pancreatitis
10.1053/j.gastro.2018.01.032 · 2018 · External reference
Espen Practical Guideline on Clinical Nutrition in Acute and Chronic Pancreatitis
10.1016/j.clnu.2023.12.019 · 2024 · External reference
Design and Validation of a Patient‐Reported Outcome Measure Scale in Acute Pancreatitis: The Pan‐Promise Study
10.1136/gutjnl-2020-320729 · 2021 · External reference
Molecular Mechanisms of Pain in Acute Pancreatitis: Recent Basic Research Advances and Therapeutic Implications
10.3389/fnmol.2023.1331438 · 2023 · External reference
Pain Intensity and Prognosis of Acute Pancreatitis in an International, Prospective Study
10.1093/bjs/znaf155 · 2025 · External reference
Analgesia in the Initial Management of Acute Pancreatitis: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
10.1007/s00268-021-06420-w · 2022 · External reference
A Systematic Review and Meta‐Analysis of Opioids vs Nonopioids in Acute Pancreatitis
2022 · External reference
2019 Wses Guidelines for the Management of Severe Acute Pancreatitis
10.1186/s13017-019-0247-0 · 2019 · External reference
Thoracic Epidural Analgesia: A New Approach for the Treatment of Acute Pancreatitis?
10.1186/s13054-016-1292-7 · 2016 · External reference
Epidural Anesthesia Improves Pancreatic Perfusion and Decreases the Severity of Acute Pancreatitis
10.3748/wjg.v21.i43.12448 · 2015 · External reference
The Safety and Efficacy of Epidural Anaesthesia in Acute Pancreatitis: A Systematic Review and Meta‐Analysis
10.1016/j.hpb.2022.12.004 · 2023 · External reference
International Association of Pancreatology Revised Guidelines on Acute Pancreatitis 2025: Supported and Endorsed by the American Pancreatic Association, European Pancreatic Club, Indian Pancreas Club, and Japan Pancreas Society
10.1016/j.pan.2025.04.020 · 2025 · External reference
Antibiotic Stewardship in Acute Pancreatitis
10.1093/bjs/znaf007 · 2025 · External reference
Appropriate Use of Antibiotics in Acute Pancreatitis: A Scoping Review
10.3390/antibiotics13090894 · 2024 · External reference
Efficacy and Adverse Effects of Insulin versus Plasmapheresis in Patients With Hypertriglyceridemia‐3‐Induced Acute Pancreatitis: A Systematic Review and Meta‐Analysis
2024 · External reference
Rare Dyslipidaemias, From Phenotype to Genotype to Management: A European Atherosclerosis Society Task Force Consensus Statement
10.1016/s2213-8587(19)30264-5 · 2020 · External reference
Hypertriglyceridemia‐Associated Acute Pancreatitis: Response to Continuous Insulin Infusion
10.1371/journal.pone.0260495 · 2021 · External reference
Insulin Stimulation of Adipose Tissue Lipoprotein Lipase. Use of the Euglycemic Clamp Technique
10.1172/jci110547 · 1982 · External reference
Lipoprotein Lipase and Lipolysis: Central Roles in Lipoprotein Metabolism and Atherogenesis
10.1016/s0022-2275(20)37569-6 · 1996 · External reference
Extreme Hypertriglyceridemia Managed With Insulin
10.1016/j.jacl.2014.09.004 · 2014 · External reference
Futility of Plasmapheresis, Insulin in Normoglycaemic Individuals, or Heparin in the Treatment of Hypertriglyceridaemia‐Induced Acute Pancreatitis
10.1016/s2213-8587(25)00028-2 · 2025 · External reference
Lipoprotein Lipase During Continuous Heparin Infusion: Tissue Stores Become Partially Depleted
10.1067/mlc.2001.117666 · 2001 · External reference
Effectiveness and Safety of Low Molecular Weight Heparin in the Management of Acute Pancreatitis: A Systematic Review and Meta‐Analysis
10.1186/s13017-024-00558-3 · 2024 · External reference
Low Molecular Weight Heparin Decreases Mortality and Major Complication Rates in Moderately Severe and Severe Acute Pancreatitis‐a Systematic Review and Meta‐Analysis
10.3389/fmed.2023.1241301 · 2023 · External reference
Low‐Molecular‐Weight Heparin plus Insulin in Hypertriglyceridemic Acute Pancreatitis a Randomized Clinical Trial
10.1001/jamanetworkopen.2025.42124 · 2025 · External reference
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach From the Writing Committee of the American Society for Apheresis: The Ninth Special Issue
10.1002/jca.22043 · 2023 · External reference
Early Plasmapheresis Among Patients With Hypertriglyceridemia‐Associated Acute Pancreatitis
10.1001/jamanetworkopen.2023.20802 · 2023 · External reference
Impact of Therapeutic Plasmapheresis on the Duration of Organ Failure in Patients With Hypertriglyceridemia‐Associated Acute Pancreatitis
10.1186/s13613-024-01285-3 · 2024 · External reference
Plasmapheresis in Acute Hypertriglyceridemia‐Induced Pancreatitis‐the Phip‐Juga‐Study
2025 · External reference
Factors Affecting Outcome in Acute Hypertriglyceridemic Pancreatitis Treated With Plasma Exchange: An Observational Cohort Study
10.1371/journal.pone.0102748 · 2014 · External reference
Comparable Triglyceride Reduction With Plasma Exchange and Insulin in Acute Pancreatitis—A Randomized Trial
10.3389/fmed.2022.870067 · 2022 · External reference
Analysis of the Clinical Profile and Treatment Efficiency of Hyperlipidemic Acute Pancreatitis
10.1186/s12944-024-02057-5 · 2024 · External reference
Nutrition Interventions for Adults With Dyslipidemia: A Clinical Perspective From the National Lipid Association
10.1016/j.jacl.2023.05.099 · 2023 · External reference
Atherogenic Dyslipidaemia and Residual Cardiovascular Risk: Understanding the Link to Heart Disease
10.1111/eci.70167 · 2026 · External reference
Recent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
10.1007/s11883-022-01052-4 · 2022 · External reference
Hypertriglyceridemia: The Importance of Identifying Patients at Risk
10.1080/00325481.2016.1243005 · 2016 · External reference
2019 Acc/Aha Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on clinical Practice Guidelines
10.1016/j.jacc.2019.03.009 · 2019 · External reference
Triglycerides and Cardiovascular Disease a Scientific Statement From the American Heart Association
10.1161/cir.0b013e3182160726 · 2011 · External reference
The Diagnosis and Treatment of Hypertriglyceridemia
2019 · External reference
2023 Aha/Acc/Accp/Aspc/Nla/Pcna Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
10.1161/cir.0000000000001168 · 2023 · External reference
Statins: Mechanism of Action and Effects
10.1111/j.1582-4934.2001.tb00172.x · 2001 · External reference
A Voyager Meta‐Analysis of the Impact of Statin Therapy on Low‐Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia
10.1016/j.amjcard.2016.02.011 · 2016 · External reference
New Approaches to Triglyceride Reduction: Is There any Hope Left?
10.1016/j.ajpc.2024.100648 · 2024 · External reference
Efficacy and Safety of Fenofibrate‐Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double‐Blind, Phase Iv Study
10.1016/j.clinthera.2021.08.005 · 2021 · External reference
Safety of Combined Statin and Fibrate Therapy: Risks of Liver Injury and Acute Kidney Injury in a Cohort Study From the Shizuoka Kokuho Database
10.1007/s40801-024-00426-1 · 2024 · External reference
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
10.1161/01.cir.98.19.2088 · 1998 · External reference
Unresolved reference
2022 · External reference
Ppar‐Alpha Agonist Fenofibrate Combined With Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
2021 · External reference
Limited Benefit of Triglyceride Lowering With Fibrates in Statin‐Treated Patients
10.1038/s41569-022-00814-6 · 2023 · External reference
Fibrates: Do They Still Have a Role in Therapy in 2025?
10.1007/s11883-025-01379-8 · 2025 · External reference
The Effect of Fibrates on Lowering Low‐Density Lipoprotein Cholesterol and Cardiovascular Risk Reduction: A Systemic Review and Meta‐Analysis
10.1093/eurjpc/zwad331 · 2024 · External reference
Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients With Hypertriglyceridemia and Metabolic Syndrome
10.3390/diseases11040140 · 2023 · External reference
Mechanisms for the Hypotriglyceridemic Effect of Marine Omega‐3 Fatty Acids
10.1016/j.amjcard.2005.12.024 · 2006 · External reference
Omega‐3 Fatty Acid Containing Diets Decrease Plasma Triglyceride Concentrations in Mice by Reducing Endogenous Triglyceride Synthesis and Enhancing the Blood Clearance of Triglyceride‐Rich Particles
10.1016/j.clnu.2008.02.001 · 2008 · External reference
National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin‐Treated Patients With Elevated Triglycerides and High or Very‐High Ascvd Risk
10.1016/j.jacl.2019.10.014 · 2019 · External reference
Omega‐3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
2019 · External reference
Effect of High‐Dose Omega‐3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk the Strength Randomized Clinical Trial
10.1001/jama.2020.22258 · 2020 · External reference
American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia
10.1016/j.eprac.2024.09.016 · 2025 · External reference
Niacin in Cardiovascular Disease: Recent Preclinical and Clinical Developments
10.1161/atvbaha.111.236315 · 2012 · External reference
Hps2‐Thrive Randomized Placebo‐Controlled Trial in 25 673 High‐Risk Patients of Er Niacin/Laropiprant: Trial Design, Pre‐Specified Muscle and Liver Outcomes, and Reasons for Stopping Study Treatment
10.1093/eurheartj/eht055 · 2013 · External reference
Niacin in Patients With Low Hdl Cholesterol Levels Receiving Intensive Statin Therapy
10.1056/nejmoa1107579 · 2011 · External reference
Effects of Extended‐Release Niacin With Laropiprant in High‐Risk Patients
10.1056/nejmoa1300955 · 2014 · External reference
Systematic Literature Review and Meta‐Analysis of Dual Therapy With Fenofibrate or Fenofibric Acid and a Statin versus a Double or Equivalent Dose of Statin Monotherapy
10.1185/03007995.2015.1098597 · 2015 · External reference
Fibrates in Combination With Statins in the Management of Dyslipidemia
10.1111/j.1524-6175.2005.05278.x · 2006 · External reference
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
10.1056/nejmoa1001282 · 2010 · External reference
Legacy Effect of Fibrate Add‐on Therapy in Diabetic Patients With Dyslipidemia: A Secondary Analysis of the Accordion Study
10.1186/s12933-020-01002-x · 2020 · External reference
Effectiveness of Ehealth Interventions in Improving Medication Adherence Among Patients With Cardiovascular Disease: Systematic Review and Meta‐Analysis
10.2196/58013 · 2024 · External reference
Key Elements and Theoretical Foundations for the Design and Delivery of Text Messages to Boost Medication Adherence in Patients With Diabetes, Hypertension, and Hyperlipidemia: Scoping Review
10.2196/71982 · 2025 · External reference
Acute Pancreatitis Recurrences Augment Long‐Term Pancreatic Cancer Risk
10.14309/ajg.0000000000002081 · 2023 · External reference
Diabetes Following Acute Pancreatitis
10.1016/s2468-1253(21)00019-4 · 2021 · External reference
Exocrine Pancreatic Insufficiency Following Acute Pancreatitis: Systematic Review and Meta‐Analysis
10.1007/s10620-019-05568-9 · 2019 · External reference
Recurrence for Patients With First Episode of Hypertriglyceridemia‐Induced Acute Pancreatitis: A Prospective Cohort Study
10.1016/j.jacl.2022.11.006 · 2023 · External reference
Prevention and Management of Hypertriglyceridemia‐Induced Acute Pancreatitis During Pregnancy: A Systematic Review
10.1016/j.amjmed.2021.12.006 · 2022 · External reference
Gpihbp1 Autoantibody Is an Independent Risk Factor for the Recurrence of Hypertriglyceridemia‐Induced Acute Pancreatitis
10.1016/j.jacl.2022.08.001 · 2022 · External reference
Suboptimal Management of Hypertriglyceridemia in the Outpatient Setting Is Associated With the Recurrent Pancreatitis: A Retrospective Cohort Study
10.1097/md.0000000000022887 · 2020 · External reference
Sra1, Apoa5, and Aifm2 Identified as Novel Genetic Risk Factors in Recurrent Hypertriglyceridemia‐Associated Acute Pancreatitis by Whole‐Exome Sequencing
10.1097/cm9.0000000000003663 · 2025 · External reference
Clinical and Economic Benefits Observed When Follow‐up Triglyceride Levels Are Less Than 500 Mg/Dl in Patients With Severe Hypertriglyceridemia
10.1016/j.jacl.2012.08.007 · 2012 · External reference
Apoc‐Iii as Therapeutic Target: Is It Primetime for Clinical Use?
10.1007/s11883-025-01315-w · 2025 · External reference
Influence of Ambulatory Triglyceride Levels on Risk of Recurrence in Patients With Hypertriglyceridemic Pancreatitis
10.1007/s10620-018-5226-x · 2019 · External reference
Apoc‐Iii Inhibition: From Regulatory Approval to Equitable Implementation
10.1038/s41569-026-01281-z · 2026 · External reference
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin‐Like Protein 3 Inhibitors
10.1007/s40256-025-00748-7 · 2025 · External reference
Inhibition of Angiopoietin‐Like Protein 3 or 3/8 Complex and Apoc‐Iii in Severe Hypertriglyceridemia
10.1007/s11883-023-01179-y · 2023 · External reference
Angptl3 and Apoc‐Iii Inhibitors for Treating Hypertriglyceridemia in Context: Horses for Courses?
10.1097/mol.0000000000000920 · 2024 · External reference
Unresolved reference
2019 · External reference
Unresolved reference
External reference
Unresolved reference
2026 · External reference
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
10.1056/nejmoa2512761 · 2026 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Safety and Efficacy of a Novel Angptl4 Inhibitory Antibody for Lipid Lowering: Results From Phase 1 and Phase 1b/2a Clinical Studies
10.1016/s0140-6736(25)00825-6 · 2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Efficacy and Long‐Term Safety of Alipogene Tiparvovec (Aav1‐Lpls447x) Gene Therapy for Lipoprotein Lipase Deficiency: An Open‐Label Trial
10.1038/gt.2012.43 · 2013 · External reference
Alipogene Tiparvovec: A Review of Its Use in Adults With Familial Lipoprotein Lipase Deficiency
10.1007/s40265-014-0339-9 · 2015 · External reference
Apoc‐Iii Inhibits Clearance of Triglyceride‐Rich Lipoproteins Through Ldl Family Receptors
10.1172/jci86610 · 2016 · External reference
Apoc3 Sirna and Aso Therapy for Dyslipidemia
10.1097/med.0000000000000857 · 2024 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2025 · External reference
Safety and Efficacy of Antisense Oligonucleotides on Triglyceride, Apolipoprotein C‐Iii, and Other Lipid Parameters Levels in Hypertriglyceridemia; a Network Meta‐Analysis of Randomized Controlled Trials
10.1186/s12944-024-02389-2 · 2025 · External reference
Recent Advances in Treating Hypertriglyceridemia in Patients at High Risk of Cardiovascular Disease With Apolipoprotein C‐Iii Inhibitors
10.1080/14656566.2023.2206015 · 2023 · External reference
Angiopoietin‐Like Protein 3 Governs Ldl‐Cholesterol Levels Through Endothelial Lipase‐Dependent Vldl Clearance
10.1194/jlr.ra120000888 · 2020 · External reference
Angiopoietin‐Like 3 Monomers Are Abundant in Human Plasma but Are Unable to Inhibit Endothelial Lipase
10.1172/jci.insight.197827 · 2025 · External reference
Angptl3 and Residual Atherosclerotic Risk: From Lipid Metabolism to Therapeutic Targeting
10.3389/fendo.2025.1706091 · 2025 · External reference
Inhibition of the Angptl3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular Disease
10.1007/s11883-024-01254-y · 2024 · External reference
Advances in Dyslipidaemia Treatments: Focusing on Apoc3 and Angptl3 Inhibitors
10.12997/jla.2024.13.1.2 · 2024 · External reference
Targeting Apoc‐Iii and Angptl3 in the Treatment of Hypertriglyceridemia
10.1080/14779072.2020.1768848 · 2020 · External reference
Broadening the Scope of Dyslipidemia Therapy by Targeting Apoc3 (Apolipoprotein C3) and Angptl3 (Angiopoietin‐Like Protein 3)
10.1161/atvbaha.122.317966 · 2023 · External reference
Durability and Efficacy of Solbinsiran, a Galnac‐Conjugated Sirna Targeting Angptl3, in Adults With Mixed Dyslipidaemia (Prolong‐Ang3): a Double‐Blind, Randomised, Placebo‐Controlled, Phase 2 Trial
10.1016/s0140-6736(25)00507-0 · 2025 · External reference
Efficacy of Evinacumab in Patients With Severe Hypertriglyceridemia and a History of Severe Hypertriglyceridemia‐Related Acute Pancreatitis: A Phase 2b Trial
10.1016/j.jacl.2025.07.005 · 2025 · External reference
Gene Therapy and Genome Editing for Lipoprotein Disorders
10.1093/eurheartj/ehaf411 · 2025 · External reference
Effect of the Dgat1 Inhibitor Pradigastat on Triglyceride and Apob48 Levels in Patients With Familial Chylomicronemia Syndrome
10.1186/s12944-015-0006-5 · 2015 · External reference
15‐Year Retrospective Analysis of Glybera (Alipogene Tiparvovec) Gene Replacement Therapy for Lipoprotein Lipase Deficiency
10.1016/j.atherosclerosis.2024.118433 · 2024 · External reference
Liproxstatin‐1 Attenuates Acute Hypertriglyceridemic Pancreatitis Through Inhibiting Ferroptosis in Rats
10.1038/s41598-024-60159-7 · 2024 · External reference
Ferroptosis in Hypertriglyceridemic Acute Pancreatitis: Mechanisms and Therapeutic Implications
10.2147/jir.s567900 · 2025 · External reference
Evolocumab and Clinical Outcomes in Patients With Cardiovascular Disease
10.1056/nejmoa1615664 · 2017 · External reference
Beyond Ldl: What Role for Pcsk9 in Triglyceride‐Rich Lipoprotein Metabolism?
10.1016/j.tem.2018.03.013 · 2018 · External reference
Role of Pcsk9 Beyond Liver Involvement
10.1097/mol.0000000000000180 · 2015 · External reference
Clinical Trial Design for Triglyceride‐Rich Lipoprotein‐Lowering Therapies: Jacc Focus Seminar 3/3
10.1016/j.jacc.2023.02.034 · 2023 · External reference
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
10.1007/s40259-022-00520-2 · 2022 · External reference
High Residual Cardiovascular Risk After Lipid‐Lowering: Prime Time for Predictive, Preventive, Personalized, Participatory, and Psycho‐Cognitive Medicine
10.3389/fcvm.2023.1264319 · 2023 · External reference
Plasmapheresis Compared With Conventional Treatment for Hypertriglyceridemia‐Induced Acute Pancreatitis: A Systematic Review and Meta‐Analysis
10.1002/jca.22018 · 2023 · External reference
Prevalence, Incidence, and Definition of Severe Hypertriglyceridemia: A Comprehensive Review and Weighted Summary
10.1016/j.jacl.2025.08.012 · 2025 · External reference
Machine Learning Improves Early Prediction of Organ Failure in Hyperlipidemia Acute Pancreatitis Using Clinical and Abdominal Ct Features
10.1016/j.pan.2024.02.003 · 2024 · External reference
Construction of a Nomogram for Hypertriglyceridemic Severe Acute Pancreatitis That Includes Metabolic Indexes
10.1186/s12944-025-02702-7 · 2025 · External reference
Development and Validation of a Nomogram for Predicting the Severity of the First Episode of Hyperlipidemic Acute Pancreatitis
10.2147/jir.s459258 · 2024 · External reference
10.1007/s00261-026-05487-0
10.1007/s00261-026-05487-0 · External reference
The Next Generation of Triglyceride‐Lowering Drugs: Will Reducing Apolipoprotein C‐Iii or Angiopoietin Like Protein 3 Reduce Cardiovascular Disease?
10.1097/mol.0000000000000679 · 2020 · External reference
Pancreatic and Cardiometabolic Complications of Severe Hypertriglyceridaemia
10.1097/mol.0000000000000939 · 2024 · External reference
